Levosimendan and mortality after coronary revascularisation: a meta-analysis of randomised controlled trials.

Crit Care · 2011 · PMC3219012 · PMID 21651806

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a strong trendno p-value reported

The levosimendan versus dobutamine group showed a strong trend in favour of levosimendan but was not statistically significant (OR 0.54 95% CI 0.25 to 1.17)).

also in 5,725 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.